Business Context and Reporting Period
Company: Alterity Therapeutics Limited (a development stage enterprise)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: April 2025
Date Filed: April 8, 2025
Principal Executive Office: Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a notification of a change in substantial holding and does not contain financial statements.
Material Changes
The primary material event disclosed is a Change in substantial holding, submitted as Exhibit 99.1. Specific details regarding the nature or magnitude of this change are not included in the cover page text.
Guidance, Outlook, and Risks
The filing text does not provide guidance, outlook, management commentary, risks, contingencies, or unusual items. The document serves solely to incorporate the change in substantial holding into existing Registration Statements on Form S-8 and Form F-3.
Investor Verification Checklist
- Review Exhibit 99.1 for specific details regarding the change in substantial holding.
- Verify the impact of the substantial holding change on the company's capital structure.
- Check the referenced Registration Statements (Form S-8 and Form F-3) for updated prospectus supplements if applicable.
- Confirm the company's status as a development stage enterprise and its current cash runway, as no financial data is present in this filing.